Brokerages Set Krystal Biotech, Inc. (NASDAQ:KRYS) PT at $220.00

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have received an average rating of “Buy” from the eight research firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $220.00.

Several equities research analysts have commented on the company. Jefferies Financial Group initiated coverage on Krystal Biotech in a research note on Wednesday, March 5th. They issued a “buy” rating and a $245.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research report on Friday, February 28th. Citigroup raised their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the company a “neutral” rating in a research report on Thursday, February 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research note on Thursday, February 20th. Finally, Chardan Capital increased their price objective on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th.

Insider Activity

In other Krystal Biotech news, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now owns 1,463,711 shares of the company’s stock, valued at approximately $260,233,178.69. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is owned by insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of institutional investors have recently made changes to their positions in the company. FMR LLC lifted its holdings in Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company’s stock worth $675,833,000 after purchasing an additional 21,133 shares during the last quarter. Vanguard Group Inc. increased its position in Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock worth $450,938,000 after buying an additional 28,707 shares during the period. Avoro Capital Advisors LLC lifted its holdings in shares of Krystal Biotech by 0.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock worth $411,831,000 after buying an additional 6,600 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock worth $107,714,000 after buying an additional 11,411 shares in the last quarter. Finally, Hood River Capital Management LLC boosted its position in shares of Krystal Biotech by 2.1% in the fourth quarter. Hood River Capital Management LLC now owns 512,726 shares of the company’s stock valued at $80,324,000 after acquiring an additional 10,622 shares during the period. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $165.00 on Friday. The stock has a market cap of $4.77 billion, a price-to-earnings ratio of 55.18 and a beta of 0.75. The business has a 50 day simple moving average of $173.96 and a 200 day simple moving average of $172.21. Krystal Biotech has a 52-week low of $141.72 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping analysts’ consensus estimates of $1.29 by $0.23. The business had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm’s quarterly revenue was up 116.4% on a year-over-year basis. During the same period last year, the business posted $0.30 earnings per share. On average, analysts predict that Krystal Biotech will post 6.14 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).